Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.57 |
| ▸ | IP6K1 | Q92551 | 5/20 | 0.52 |
| ▸ | IP6K3 | Q96PC2 | 5/20 | 0.52 |
| ▸ | IP6K2 | Q9UHH9 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CAMKK1 | Q8N5S9 | 2/20 | 0.50 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15500539 | 0.88 | PIK3CA (0.55) | PIK3CAIP6K1IP6K3IP6K2ALDH1A1 | |
| SCHEMBL9907325 | 0.84 | ALOX15 (0.55) | PIK3CAALDH1A1KDM4ESMN1; SMN2CAMKK2 | |
| SCHEMBL12874476 | 0.84 | PIK3CA (0.51) | PIK3CAIP6K1IP6K3IP6K2ALDH1A1 | |
| SCHEMBL6862365 | 0.84 | PIK3CA (0.51) | PIK3CAALDH1A1KDM4ESMN1; SMN2CAMKK1 | |
| SCHEMBL9907402 | 0.83 | PIK3CA (0.44) | PIK3CAIP6K1IP6K3IP6K2ALDH1A1 | |
| SCHEMBL9909160 | 0.83 | SLC22A12 (0.58) | PIK3CACAMKK1CAMKK2KDM4CKDM5A | |
| SCHEMBL9907406 | 0.82 | KDM4C (0.52) | IP6K1IP6K3IP6K2ALDH1A1TP53 | |
| SCHEMBL9907787 | 0.82 | PIK3CA (0.49) | PIK3CA | |
| SCHEMBL9909215 | 0.80 | RXRA (0.52) | IP6K1IP6K3IP6K2SMN1; SMN2KDM4C | |
| SCHEMBL9907363 | 0.80 | DOT1L (0.44) | IP6K1IP6K3IP6K2ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| CN-112105354-A | Fibroblast activation protein inhibitor | 普拉西斯生物技术有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-3723753-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC | 2019-06-20 | — | — | US | disclosed |
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC | 2019-06-20 | — | — | US | disclosed |
| WO-2019118932-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2019-06-20 | — | — | WO | disclosed |
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FAP, FIBP, FRS2 | PIK3CA 502/4885IP6K1 970/4885IP6K3 1275/4885 |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | PIK3CA 3492/4885IP6K1 4169/4885IP6K3 4056/4885 |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | FAP, FIBP, FRS2 | PIK3CA 502/4885IP6K1 970/4885IP6K3 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.